van Roermund H P, Tiggeler R G, Berden J H, van Lier H J, Koene R A
Clin Nephrol. 1982 Jul;18(1):39-42.
Over an 18 month period 66 consecutive kidney transplant patients at risk of gastrointestinal bleeding were treated prophylactically with the histamine H2-blocker cimetidine, without antacids. The incidence of gastrointestinal bleeding, the number of rejection episodes, and graft survival were compared with those of 66 patients, who had received a transplant in the period immediately preceding the start of the study, and who had never received cimetidine. The incidence of gastrointestinal hemorrhage was significantly reduced in the cimetidine-treated patients (P less than 0.05). In addition, cimetidine treatment neither increased the total number of rejection episodes nor did it impair long-term graft survival.
在18个月的时间里，对66例有胃肠道出血风险的连续肾移植患者预防性使用组胺H2受体阻滞剂西咪替丁进行治疗，未使用抗酸剂。将这些患者的胃肠道出血发生率、排斥反应次数和移植肾存活率与66例患者进行比较，这66例患者在研究开始前的时间段接受了移植，且从未接受过西咪替丁治疗。西咪替丁治疗组患者的胃肠道出血发生率显著降低（P<0.05）。此外，西咪替丁治疗既未增加排斥反应的总数，也未损害移植肾的长期存活。
